Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Intratumoral EGFR Antisense DNA (BB-401) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Who Have Failed All Available Standard Therapies

NCT03433027 is registered in ClinicalTrials.gov with Benitec Biopharma, Inc. as lead sponsor.

NCT NCT03433027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03433027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Intratumoral EGFR Antisense DNA (BB-401) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Who Have Failed All Available Standard Therapies
Lead sponsor
Benitec Biopharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 15, 2018
Completion date
April 6, 2020
Enrollment
16 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma